Publications by authors named "Rodolfo Mattioli"

Claim this Profile
C
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
Marina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, Antonio Bernardo, Laura Biganzoli, Rodolfo Mattioli

Cancers (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer: The HuCare2 Stepped-Wedge Cluster Randomized Trial.
Caterina Caminiti, Maria Antonietta Annunziata, Claudio Verusio, Carmine Pinto, Mario Airoldi, Rodolfo Mattioli

JAMA Netw Open· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to improve the identification of patients with cancer eligible for genetic counselling?
Raffaella Bracci, Beatrice Gasperini, Maria Capalbo, Tamara Campanelli, Eleonora Caimmi, Rodolfo Mattioli

Eur J Cancer Care (Engl)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Gerardo Rosati, Fabio Galli, Maurizio Cantore, Francesca Bergamo, Maria Banzi, Rodolfo Mattioli

Oncologist· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Fausto Petrelli, Roberto Labianca, Alberto Zaniboni, Sara Lonardi, Fabio Galli, Rodolfo Mattioli

JAMA Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Vincenzo Catalano, Francesca Bergamo, Chiara Cremolini, Bruno Vincenzi, Francesca Negri, Rodolfo Mattioli

J Cancer Res Clin Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility single-arm study of a medical device containing and combined with chemotherapy in head and neck cancer patients.
Luca Imperatori, Damiano Giardini, Gino Latini, Giuseppe Migliori, Claudio Blasi, Rodolfo Mattioli

Cancer Manag Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients.
Sebastiano Mercadante, Paolo Marchetti, Arturo Cuomo, Augusto Caraceni, Rocco Domenico Mediati, Rodolfo Mattioli

Cancers (Basel)· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.
Gianluca Tomasello, Nicola Valeri, Michele Ghidini, Elizabeth C Smyth, Wanda Liguigli, Rodolfo Mattioli

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS).
Sebastiano Mercadante, Paolo Marchetti, Arturo Cuomo, Augusto Caraceni, Rocco Domenico Mediati, Rodolfo Mattioli

Adv Ther· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Antonello Veccia, Orazio Caffo, Ugo De Giorgi, Giuseppe Di Lorenzo, Cinzia Ortega, Rodolfo Mattioli

Future Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Ann Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Sergio Bracarda, Angela Gernone, Donatello Gasparro, Paolo Marchetti, Monica Ronzoni, Rodolfo Mattioli

Future Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Andrea Ardizzoni, Marcello Tiseo, Luca Boni, Andrew D Vincent, Rodolfo Passalacqua, Rodolfo Mattioli

J Clin Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.
Marco Montanari, Francesco Fabbri, Ermanno Rondini, Giovanni Luca Frassineti, Rodolfo Mattioli

Tumori· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.
Mario Airoldi, Dino Amadori, Sandro Barni, Saverio Cinieri, Sabino De Placido, Rodolfo Mattioli

Tumori· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Giuseppe Colucci, Francesco Giuliani, Carlo Garufi, Rodolfo Mattioli, Luigi Manzione

Oncology· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy.
Laura Doni, Alessandra Perin, Luigi Manzione, Vittorio Gebbia, Rodolfo Mattioli

Crit Rev Oncol Hematol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Sebastiano Buti, Silvia Lazzarelli, Matteo Dalla Chiesa, Cecilia Simonelli, Giovanni Lo Re, Rodolfo Mattioli

J Immunother· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.
Cesare Gridelli, Alessandro Morabito, Vittorio Gebbia, Manlio Mencoboni, Francesco Carrozza, Rodolfo Mattioli

Lung Cancer· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
Rodolfo Mattioli, Cesare Gridelli, Javier Castellanos, Antonio Duque, Alfredo Falcone

Clin Transl Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer.
Annamaria Ruzzo, Emanuele Canestrari, Paolo Maltese, Francesca Pizzagalli, Francesco Graziano, Rodolfo Mattioli

Clin Chem Lab Med· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy.
Filippo Grillo-Ruggieri, Giovanna Mantello, Rossana Berardi, Massimo Cardinali, Francesco Fenu, Rodolfo Mattioli

Dis Colon Rectum· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Annamaria Ruzzo, Francesco Graziano, Fotios Loupakis, Eliana Rulli, Emanuele Canestrari, Rodolfo Mattioli

J Clin Oncol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Cristian Massacesi, Salvatore Terrazzino, Fabiana Marcucci, Marco B Rocchi, Paolo Lippe, Rodolfo Mattioli

Cancer· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis